• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Engineering TCR-preserved allogeneic CAR-T cells: leveraging cancer immune evasion principles to establish T-cell tolerance.

作者信息

Zheng Xiaodong, Tian Zhigang

机构信息

State Key Laboratory of Immune Response and Immunotherapy, Institute of Immunology, Biomedical Sciences and Health Laboratory of Anhui Province, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, China.

Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

出版信息

Cell Mol Immunol. 2025 Aug 26. doi: 10.1038/s41423-025-01341-3.

DOI:10.1038/s41423-025-01341-3
PMID:40855002
Abstract
摘要

相似文献

1
Engineering TCR-preserved allogeneic CAR-T cells: leveraging cancer immune evasion principles to establish T-cell tolerance.工程化保留TCR的同种异体CAR-T细胞：利用癌症免疫逃逸原理建立T细胞耐受性。
Cell Mol Immunol. 2025 Aug 26. doi: 10.1038/s41423-025-01341-3.
2
Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells.通过利用同种异体嵌合抗原受体自然杀伤T细胞（CAR-NKT细胞）克服卵巢癌对CAR-T细胞疗法的耐药性和逃避现象。
Med. 2025 Aug 5:100804. doi: 10.1016/j.medj.2025.100804.
3
A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape.一种新型CD3ε融合受体可使T细胞衔接子用于无T细胞受体的同种异体嵌合抗原受体（CAR）T细胞，以提高活性并防止抗原逃逸。
Mol Ther. 2025 May 28. doi: 10.1016/j.ymthe.2025.05.030.
4
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy.聚糖屏蔽可实现TCR充足的同种异体CAR-T疗法。
Cell. 2025 Aug 14. doi: 10.1016/j.cell.2025.07.046.
5
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
6
Monovalent Anti-CD3 Antibodies Effectively Eliminate the TCR-Positive Fraction of TCR-Deleted Allogeneic CAR-T Cells to Prevent GVHD.单价抗CD3抗体可有效清除TCR缺失的同种异体CAR-T细胞中的TCR阳性部分，以预防移植物抗宿主病。
Immune Netw. 2024 Dec 24;24(6):e43. doi: 10.4110/in.2024.24.e43. eCollection 2024 Dec.
7
Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.通过人疱疹病毒 8 蛋白调节 MHC 表面表达对同种异体 CAR-T 细胞的工程宽容。
Mol Ther. 2021 Feb 3;29(2):718-733. doi: 10.1016/j.ymthe.2020.10.019. Epub 2020 Oct 22.
8
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.通用异体嵌合抗原受体 T 细胞，采用睡眠美人转座子和 CRISPR-CAS9 技术用于癌症免疫治疗。
Mol Ther. 2022 Oct 5;30(10):3155-3175. doi: 10.1016/j.ymthe.2022.06.006. Epub 2022 Jun 16.
9
Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends.用于实体瘤的下一代嵌合抗原受体T细胞（CAR-T）和T细胞受体T细胞（TCR-T）疗法：创新、挑战与全球发展趋势
Cancers (Basel). 2025 Jun 11;17(12):1945. doi: 10.3390/cancers17121945.
10
CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products.用 CAR NK-92 细胞清除残留 TCR+细胞，以获得超高纯度的异体 TCR 缺失 CAR T 细胞产品。
Blood Adv. 2023 Aug 8;7(15):4124-4134. doi: 10.1182/bloodadvances.2022009397.

本文引用的文献

1
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.异基因嵌合抗原受体T细胞产品西马卡布他基因安塞吉德列塞尔/ALLO-501用于复发/难治性大B细胞淋巴瘤：来自ALPHA2/ALPHA临床研究的I期经验
J Clin Oncol. 2025 May 10;43(14):1695-1705. doi: 10.1200/JCO-24-01933. Epub 2025 Feb 13.
2
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.用于癌症治疗的异基因嵌合抗原受体细胞疗法：取得的进展与尚存的障碍
Nat Rev Clin Oncol. 2025 Jan;22(1):10-27. doi: 10.1038/s41571-024-00959-y. Epub 2024 Nov 15.
3
Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.
使用 eliglustat 抑制糖脂合成与免疫检查点抑制剂联合用于晚期癌症：临床前证据和 I 期临床试验。
Nat Commun. 2024 Aug 14;15(1):6970. doi: 10.1038/s41467-024-51495-3.
4
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.鉴定 NOXA 作为 B 细胞恶性肿瘤中 CAR T 细胞治疗耐药的关键调节因子。
Signal Transduct Target Ther. 2022 Apr 4;7(1):98. doi: 10.1038/s41392-022-00915-1.
5
CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma.用于复发/难治性淋巴瘤患者的CRISPR/Cas9基因组编辑通用嵌合抗原受体T细胞
Blood Adv. 2022 Apr 26;6(8):2695-2699. doi: 10.1182/bloodadvances.2021006232.
6
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.抗 PD-1 和 TCR 嵌合抗原受体 T 细胞治疗间皮素阳性实体瘤的 I 期临床研究。
Cell Mol Immunol. 2021 Sep;18(9):2188-2198. doi: 10.1038/s41423-021-00749-x. Epub 2021 Aug 11.
7
Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.突变体 B2M-HLA-E 和 B2M-HLA-G 融合蛋白可保护通用嵌合抗原受体修饰的 T 细胞免受同种异体 NK 细胞介导的裂解。
Eur J Immunol. 2021 Oct;51(10):2513-2521. doi: 10.1002/eji.202049107. Epub 2021 Aug 19.
8
The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses.SPPL3 定义的糖鞘脂库协调 HLA I 类介导的免疫反应。
Immunity. 2021 Feb 9;54(2):387. doi: 10.1016/j.immuni.2021.01.016.
9
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.基因编辑的、供体来源的同种异体抗 CD19 嵌合抗原受体 T 细胞治疗儿童和成人 B 细胞急性淋巴细胞白血病：两项 1 期研究结果。
Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.
10
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.经通用 TALEN 基因编辑 CAR T 细胞输注后婴儿 B-ALL 达到分子缓解。
Sci Transl Med. 2017 Jan 25;9(374). doi: 10.1126/scitranslmed.aaj2013.